Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk

Abstract

Platelets are activated by the interaction with cancer cells and release enhanced levels of lipid mediators [such as thromboxane (TX)A 2 and prostaglandin (PG)E 2, generated from arachidonic acid (AA) by the activity of cyclooxygenase (COX)-1], granule content, including ADP and growth factors, chemokines, proteases and Wnt proteins. Moreover, activated platelets shed different vesicles, such as microparticles (MPs) and exosomes (rich in genetic material such as mRNAs and miRNAs).These platelet-derived products induce several phenotypic changes in cancer cells which confer high metastatic capacity. A central event involves an aberrant expression of COX-2 which influences cell-cycle progression and contribute to the acquisition of a cell migratory phenotype through the induction of epithelial mesenchymal transition genes and downregulation of E-cadherin expression. The identification of novel molecular determinants involved in the crosstalk between platelets and cancer cells has led to identify novel targets for anti-cancer drug development.